Table 2.
Correlation of UBE2C Copy Number with Clinicopathologic Parameters in CRC
| Total no. (%) | Amplified, no (%)⁎ | Nonamplified, no. (%) | P value | |
|---|---|---|---|---|
| Total no. of cases | 371 | 114 (30.7) | 257 (69.3) | |
| Age | ||||
| ≤50 years | 130 (35.0) | 40 (30.8) | 90 (69.2) | 0.9899 |
| >50 years | 241 (65.0) | 74 (30.7) | 167 (69.3) | |
| Sex | ||||
| Male | 176 (47.4) | 50 (28.4) | 126 (71.6) | 0.3573 |
| Female | 195 (52.6) | 64 (32.8) | 131 (67.2) | |
| Tumor site | ||||
| Descending colon | 309 (83.3) | 97 (31.4) | 212 (68.6) | 0.5326 |
| Ascending colon | 62 (16.7) | 17 (27.4) | 45 (72.6) | |
| Histologic type | ||||
| Adenocarcinoma | 315 (84.9) | 104 (33.0) | 211 (67.0) | 0.0181 |
| Mucinous carcinoma | 56 (15.1) | 10 (17.9) | 46 (82.1) | |
| Tumor stage | ||||
| I | 55 (15.6) | 20 (36.4) | 35 (63.6) | 0.0838 |
| II | 116 | 28 (24.0) | 88 (76.0) | |
| III | 135 (38.4) | 40 (29.6) | 95 (70.4) | |
| IV | 46 (13.1) | 20 (43.5) | 26 (56.5) | |
| Differentiation | ||||
| Well | 32 (8.6) | 11 (34.4) | 21 (65.6) | 0.5864 |
| Moderate | 266 (71.7) | 84 (3.6) | 182 (68.4) | |
| Poor | 73 (19.7) | 19 (26.0) | 54 (74.0) | |
| Cyclin A† | ||||
| High expression | 273 (81.0) | 89 (32.6) | 184 (67.4) | 0.2299 |
| Low expression | 64 (19.0) | 16 (25.0) | 48 (75.0) | |
| Cyclin B1† | ||||
| High expression | 290 (85.5) | 98 (33.8) | 195 (66.2) | 0.0037 |
| Low expression | 49 (14.5) | 7 (14.3) | 42 (85.7) | |
| Ki-67† | ||||
| High expression | 297 (85.3) | 101 (34.0) | 196 (66.0) | 0.0152 |
| Low expression | 51 (14.7) | 9 (17.6) | 42 (82.4) | |
| 5-year overall survival, % | 65.2 | 70.9 | 0.4190 |
⁎
UBE2C amplified: tissue samples were classified with a UBE2C centromere 20 ratio of 1.0 as normal, between 1.0 and 2.0 as having UBE2C gains, and of >2.0 as amplified.
†
Analysis failure of some IHC markers was attributed to missing or nonrepresentative spots.